TY  - JOUR

T1  - Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 Trial

JO  - Dermatology and Therapy

UR  - https://doi.org/10.1007/s13555-026-01745-7

PY  - 2026/04/25

AU  - Paller AS

AU  - Cork MJ

AU  - Hong HC-H

AU  - Soong W

AU  - Schneider SKR

AU  - Lo H

AU  - Vinther F

AU  - Thøgersen P

AU  - Wollenberg A

ED  - 

DO  - DOI: 10.1007/s13555-026-01745-7

PB  - Springer Science and Business Media LLC

Y2  - 2026/05/14

ER  -